open access

Vol 82, No 12 (2011)
ARTICLES
Get Citation

Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy

Jolanta Mrochem-Kwarciak, Izolda Mrochen-Domin, Andrzej Wojcieszek, Regina Deja, Aleksandra Chmura, Barbara Masłyk, Elżbieta Nowara, Beata Kaleta, Zofia Kołosza, Wiesława Bartnik
Ginekol Pol 2011;82(12).

open access

Vol 82, No 12 (2011)
ARTICLES

Abstract

Abstract Introduction: Currently CA 125 is a marker of choice for monitoring ovarian cancer. Nonetheless, scientists are still searching for new markers, which could provide additional information for the evaluation of treatment, especially in patients with normal CA 125 levels, despite the progression of the disease. According to the latest reports, OPN can be a potential new marker. Aim: Estimation of usefulness of OPN determinations in the monitoring of ovarian cancer patients. Material and Methods: The study included 54 ovarian cancer patients, undergoing chemotherapy. Markers were measured before, during and after treatment. The dynamics of the change of OPN levels was shown on line graphs, using Microsoft Excel programme. Statistical analysis was performed by Kaplan-Meier method and log-rank test. Results: 44% of patients from the study group were found to have low CA 125 levels. In these cases only the increase of OPN concentration indicated recurrence of the disease. In 43% of patients the high initial CA 125 and OPN levels decreased during chemotherapy and complete regression was stated in these patients. Nevertheless, in 13/17 patients a repeated increase of OPN concentration signalling the recurrence, earlier than CA 125 and clinical recurrence manifestation, was observed. In 13% of patients high initial levels of markers did not decrease during chemotherapy, which correlated with the progression of the disease. Our study showed that only the CA 125 levels had a significant influence (p=0.00063) on the disease-free survival time. Conclusions: Our data suggest a potential usefulness of the OPN determinations in estimating ovarian cancer recurrence. Nonetheless, there was no correlation between the initial OPN concentration and the disease-free survival time.

Abstract

Abstract Introduction: Currently CA 125 is a marker of choice for monitoring ovarian cancer. Nonetheless, scientists are still searching for new markers, which could provide additional information for the evaluation of treatment, especially in patients with normal CA 125 levels, despite the progression of the disease. According to the latest reports, OPN can be a potential new marker. Aim: Estimation of usefulness of OPN determinations in the monitoring of ovarian cancer patients. Material and Methods: The study included 54 ovarian cancer patients, undergoing chemotherapy. Markers were measured before, during and after treatment. The dynamics of the change of OPN levels was shown on line graphs, using Microsoft Excel programme. Statistical analysis was performed by Kaplan-Meier method and log-rank test. Results: 44% of patients from the study group were found to have low CA 125 levels. In these cases only the increase of OPN concentration indicated recurrence of the disease. In 43% of patients the high initial CA 125 and OPN levels decreased during chemotherapy and complete regression was stated in these patients. Nevertheless, in 13/17 patients a repeated increase of OPN concentration signalling the recurrence, earlier than CA 125 and clinical recurrence manifestation, was observed. In 13% of patients high initial levels of markers did not decrease during chemotherapy, which correlated with the progression of the disease. Our study showed that only the CA 125 levels had a significant influence (p=0.00063) on the disease-free survival time. Conclusions: Our data suggest a potential usefulness of the OPN determinations in estimating ovarian cancer recurrence. Nonetheless, there was no correlation between the initial OPN concentration and the disease-free survival time.
Get Citation

Keywords

ovarian cancer, osteopontin, first-line chemotherapy

About this article
Title

Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy

Journal

Ginekologia Polska

Issue

Vol 82, No 12 (2011)

Bibliographic record

Ginekol Pol 2011;82(12).

Keywords

ovarian cancer
osteopontin
first-line chemotherapy

Authors

Jolanta Mrochem-Kwarciak
Izolda Mrochen-Domin
Andrzej Wojcieszek
Regina Deja
Aleksandra Chmura
Barbara Masłyk
Elżbieta Nowara
Beata Kaleta
Zofia Kołosza
Wiesława Bartnik

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl